Federico Innocenti
Federico Innocenti
Verified email at
Cited by
Cited by
Comprehensive and integrative genomic characterization of hepatocellular carcinoma
A Ally, M Balasundaram, R Carlsen, E Chuah, A Clarke, N Dhalla, RA Holt, ...
Cell 169 (7), 1327-1341. e23, 2017
Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan
F Innocenti, SD Undevia, L Iyer, P Xian Chen, S Das, M Kocherginsky, ...
Journal of Clinical Oncology 22 (8), 1382-1388, 2004
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)
HL Kindler, D Niedzwiecki, D Hollis, S Sutherland, D Schrag, H Hurwitz, ...
Journal of Clinical Oncology 28 (22), 3617, 2010
Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a …
AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, B Fruth, JA Meyerhardt, ...
Jama 317 (23), 2392-2401, 2017
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts …
AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, MR Mahoney, BH O'Neil, ...
Journal of Clinical Oncology 32 (15_suppl), LBA3-LBA3, 2014
Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB …
AP Venook, D Niedzwiecki, F Innocenti, B Fruth, C Greene, BH O'Neil, ...
Journal of Clinical Oncology 34 (15_suppl), 3504-3504, 2016
Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer
BM Wolpin, C Rizzato, P Kraft, C Kooperberg, GM Petersen, Z Wang, ...
Nature genetics 46 (9), 994-1000, 2014
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics
F Innocenti, DL Kroetz, E Schuetz, ME Dolan, J Ramírez, M Relling, ...
Journal of Clinical Oncology 27 (16), 2604, 2009
Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome
F Innocenti, FS Ou, X Qu, TJ Zemla, D Niedzwiecki, R Tam, S Mahajan, ...
Journal of Clinical Oncology 37 (14), 1217, 2019
Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue
F Innocenti, GM Cooper, IB Stanaway, ER Gamazon, JD Smith, S Mirkov, ...
PLoS genetics 7 (5), e1002078, 2011
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
A Dasari, VK Morris, CJ Allegra, C Atreya, AB Benson III, P Boland, ...
Nature reviews Clinical oncology 17 (12), 757-770, 2020
Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated …
E Cecchin, F Innocenti, M D'Andrea, G Corona, E De Mattia, P Biason, ...
Journal of Clinical Oncology 27 (15), 2457-2465, 2009
Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB/SWOG 80405 (Alliance)
HJ Lenz, FS Ou, AP Venook, HS Hochster, D Niedzwiecki, RM Goldberg, ...
Journal of Clinical Oncology 37 (22), 1876, 2019
Ethnic differences and functional analysis of MET mutations in lung cancer
S Krishnaswamy, R Kanteti, JS Duke-Cohan, S Loganathan, W Liu, ...
Clinical Cancer Research 15 (18), 5714-5723, 2009
A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter
W Liu, F Innocenti, MH Wu, AA Desai, ME Dolan, EH Cook Jr, MJ Ratain
Cancer research 65 (1), 46-53, 2005
Effect of methylenetetrahydrofolate reductase 677C→ T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients
G Toffoli, A Russo, F Innocenti, G Corona, S Tumolo, F Sartor, E Mini, ...
International journal of cancer 103 (3), 294-299, 2003
A pharmacogenetic study of uridine diphosphate–glucuronosyltransferase 2B7 in patients receiving morphine
MB Sawyer, F Innocenti, S Das, C Cheng, J Ramírez, FH Pantle‐Fisher, ...
Clinical Pharmacology & Therapeutics 73 (6), 566-574, 2003
Clinical pharmacology and pharmacogenetics of gemcitabine
A Wong, RA Soo, WP Yong, F Innocenti
Drug metabolism reviews 41 (2), 77-88, 2009
Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups
F Innocenti, C Grimsley, S Das, J Ramírez, C Cheng, H Kuttab-Boulos, ...
Pharmacogenetics and Genomics 12 (9), 725-733, 2002
Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin
K Zhou, SW Yee, EL Seiser, N Van Leeuwen, R Tavendale, AJ Bennett, ...
Nature genetics 48 (9), 1055-1059, 2016
The system can't perform the operation now. Try again later.
Articles 1–20